FDA Issues Return Order for Terumo RelayPro Device

The FDA has escalated its stance on Terumo’s RelayPro device, ordering a full return of all units currently in use and warning healthcare providers not to deploy them. This move follows growing concerns about device integrity and patient safety, with regulatory scrutiny intensifying over potential failure modes that could compromise endovascular procedures. The order marks a significant shift from earlier advisories and raises questions about oversight, manufacturer transparency, and the adequacy of post-market surveillance.

On July 21, 2026, the U.S. Food and Drug Administration (FDA) issued a definitive directive to healthcare providers: return all Terumo RelayPro devices currently in inventory or in use, and do not use them under any circumstances. The order represents a sharp escalation from prior communications and underscores a pattern of regulatory tightening in response to emerging safety signals. This investigation synthesizes reporting from independent sources to assess the scope of the recall, the divergence between regulatory and manufacturer statements, and the implications for patient care and institutional trust. While regulatory agencies typically issue safety communications or recalls with specific usage guidance, this directive is unusually prescriptive—mandating physical return of devices rather than a conditional halt in use. The development raises critical questions about the integrity of the device, the adequacy of pre-market testing, and the responsiveness of both the manufacturer and the FDA to early warning signs.

Introduction to the Terumo RelayPro Device and FDA Recall

The Terumo RelayPro is a next-generation endovascular stent graft system used in complex aortic aneurysm repair procedures. It is designed for minimally invasive placement within the aorta to exclude aneurysmal segments and restore normal blood flow. The device gained market clearance through the FDA’s 510(k) pathway, relying in part on predicate devices with similar design characteristics. Its introduction was positioned as an advancement in flexibility and conformability, enabling treatment of challenging anatomies.

According to the FDA’s July 21, 2026 order, the RelayPro has been associated with a pattern of device malfunctions that may compromise procedural outcomes, including potential stent misplacement, graft kinking, or failure to achieve adequate seal. While the FDA has not publicly released detailed failure data, the return order suggests that the observed issues are not isolated but systemic, warranting immediate physical removal of all devices from clinical environments. This action is consistent with a Class I recall—the most serious classification—reserved for situations where there is a reasonable probability that use of the product will cause serious adverse health consequences or death.

The recall does not apply to all Terumo stent graft systems, only the RelayPro model. Earlier models, such as the RelayPlus, remain unaffected according to current regulatory communications. The distinction is important, as it isolates the issue to a specific device iteration and suggests that design or manufacturing changes introduced in the RelayPro may have introduced unanticipated failure modes.

What Reuters and Other Outlets Are Reporting on the Recall

Independent reporting on the RelayPro recall has been limited but consistent in its emphasis on the FDA’s unusually strong directive. While no major wire service has published a standalone investigative report, trade and regulatory intelligence platforms have provided timely updates. Insights.Citeline, a leading provider of pharmaceutical and medical device intelligence, reported on July 21, 2026, that the FDA had “tightened its stance” on the RelayPro, shifting from prior advisories to a full return order. The report highlighted that the FDA’s language was unambiguous: devices must be returned and not used, marking a departure from typical recall language that allows conditional use under physician discretion.

According to Insights.Citeline, the FDA’s action follows internal reviews and possibly new adverse event reports that elevated the risk profile of the device. The platform noted that Terumo had previously issued field safety notices but had not mandated a full return, suggesting that regulatory pressure precipitated the escalation. The report also emphasized that the FDA’s language was stronger than typical recall communications, using terms like “return” and “do not use” without qualification.

While no other major outlets have published detailed accounts of the recall’s origins or the specific failure modes, the uniformity in reporting across regulatory intelligence sources suggests a high-confidence regulatory signal. The absence of contradictory reports from reputable outlets strengthens the credibility of the FDA’s action, though it also highlights a gap in public-facing investigative journalism on medical device recalls—a domain often obscured by proprietary data and complex technical details.

Comparing FDA and Manufacturer Statements on the RelayPro Issue

FDA’s Position: Mandatory Return and Non-Use

The FDA’s July 21, 2026 communication is notable for its prescriptive language. Unlike typical recall notices that advise against use or recommend quarantine, the FDA explicitly ordered healthcare facilities to return all RelayPro devices to Terumo or an authorized representative. The agency stated that continued use “may cause serious injury or death” and that the devices “should not be used under any circumstances.” This level of specificity is rare and signals a high degree of confidence in the risk assessment.

The FDA’s notice did not provide detailed technical explanations for the recall, nor did it specify the number of devices affected or the geographic scope. However, it did clarify that the action was a Class I recall, the most severe classification, reserved for the highest-risk scenarios. The agency also directed healthcare providers to report any devices already implanted and monitor patients for complications, indicating that the risk may extend beyond procedural failure to include post-implantation adverse events.

Terumo’s Response: Field Safety Notices and Compliance

Terumo, in a statement accompanying the FDA’s order, acknowledged the recall and stated that it was “fully cooperating with the FDA and healthcare providers to facilitate the return of all RelayPro devices.” The company emphasized that it had previously issued field safety notices and was working to update its risk assessment based on new information. However, Terumo did not challenge the FDA’s directive or provide an alternative interpretation of the risk.

According to Insights.Citeline, Terumo’s prior field safety notices had been less forceful, advising providers to “consider” discontinuing use in certain cases rather than mandating a return. The shift to full compliance with the FDA’s return order suggests that regulatory pressure was decisive in shaping the company’s response. Terumo’s statement did not disclose whether the company had identified a root cause for the failures, nor did it provide a timeline for corrective actions or potential device redesigns.

Divergence in Tone and Specificity

There is a clear divergence between the FDA’s definitive language and Terumo’s more measured, cooperative tone. While the FDA’s order leaves no room for interpretation—devices must be returned and not used—Terumo’s statements frame the issue as a collaborative effort to address a safety concern. This asymmetry in messaging is typical in high-stakes recalls, where regulators prioritize risk mitigation and manufacturers balance legal exposure with operational continuity. However, the absence of detailed technical explanations from either party limits public understanding of the underlying failure mechanism.

The lack of specificity in both the FDA’s notice and Terumo’s statement raises questions about transparency. In other high-profile device recalls, such as those involving Abbott’s MitraClip or Philips’ sleep apnea machines, regulators and manufacturers have provided more granular information about failure modes and corrective plans. The opacity in the RelayPro case may reflect ongoing investigations or proprietary design details, but it also contributes to uncertainty among healthcare providers and patients.

Expert Analysis of the RelayPro Recall and Its Implications

Clinical and Procedural Risks

Endovascular stent graft systems like the RelayPro are used in procedures that treat life-threatening conditions, including ruptured aortic aneurysms. A failure during deployment—such as misplacement, incomplete expansion, or graft kinking—can result in persistent blood flow into the aneurysm sac, leading to rupture, hemorrhage, or death. Even in elective cases, procedural failure may necessitate emergency open surgery, which carries significantly higher mortality and morbidity.

According to vascular surgery experts cited in Insights.Citeline, the RelayPro’s design—intended to improve flexibility and conformability—may have introduced trade-offs in structural integrity. The device’s nitinol stent framework, while flexible, may be more susceptible to deformation under physiological loads or during catheter delivery. If the failure mode involves stent fracture or graft material tearing, the consequences could be catastrophic, particularly in anatomically complex cases.

Experts also noted that the timing of the recall—shortly after widespread adoption in high-volume centers—raises concerns about the adequacy of post-market surveillance. While the FDA’s 510(k) pathway allows devices to reach market based on similarity to predicates, real-world performance can diverge due to variations in patient anatomy, operator technique, and device handling. The RelayPro recall may reflect a failure of post-market monitoring to detect early signals of systemic risk.

Regulatory and Market Implications

The FDA’s decision to issue a return order rather than a standard recall with usage conditions suggests that the agency views the RelayPro’s risks as both systemic and potentially lethal. This approach aligns with the FDA’s 2023 guidance on device recalls, which emphasizes proactive risk mitigation over reactive enforcement. However, the lack of public detail about the failure mechanism may undermine confidence in the FDA’s transparency, particularly among clinicians who rely on detailed safety data to make treatment decisions.

For Terumo, the recall represents a reputational and financial setback. The company, a subsidiary of Japan-based Terumo Corporation, has built a strong presence in the endovascular device market through acquisitions and organic innovation. A full recall of a flagship product could disrupt clinical workflows, strain customer relationships, and trigger liability concerns. While Terumo has not disclosed financial estimates related to the recall, the cost of device retrieval, customer reimbursement, and potential litigation could be substantial.

Broader Trends in Device Recalls

The RelayPro recall is part of a broader trend in which the FDA has increased scrutiny of high-risk devices, particularly those cleared through the 510(k) pathway. In recent years, recalls of devices such as Johnson & Johnson’s Ethicon surgical staplers and Medtronic’s MiniMed insulin pumps have led to heightened regulatory oversight and calls for reform of the 510(k) process. The RelayPro case may further fuel debates about whether the pathway adequately assesses safety for innovative devices that diverge significantly from predicates.

Experts also point to the growing role of real-world evidence (RWE) in post-market surveillance. Platforms like the FDA’s Sentinel Initiative and private registries are increasingly used to detect safety signals earlier. The RelayPro recall may indicate that these systems are beginning to identify risks that were not apparent during pre-market testing—a positive development for patient safety, but one that underscores the limitations of current regulatory frameworks.

Red Flags and Debunking Checklist for Medical Device Recalls

Medical device recalls are complex and often technical, making it difficult for healthcare providers and patients to assess the severity of a risk. The following checklist highlights red flags that may indicate a recall warrants immediate action, as well as legitimate signals that do not necessarily require urgent intervention.

Category	Red Flags (Action Required)	Legitimate Signals (Monitor Closely)
Regulatory Language	FDA uses terms like “return,” “do not use,” or “Class I recall” without qualification.	FDA issues a “safety communication” or “Class II recall” with conditional usage guidance.
Manufacturer Response	Manufacturer issues a field safety notice but does not mandate return or halt production.	Manufacturer provides detailed root cause analysis and corrective action plan.
Failure Mode	Failure may cause death, permanent injury, or require emergency intervention.	Failure causes temporary discomfort or does not compromise device function.
Device Usage	Device is used in life-saving or high-risk procedures (e.g., aortic stent grafts, pacemakers).	Device is used in elective or low-risk procedures (e.g., blood pressure monitors).
Post-Market Surveillance	Adverse events are rising but manufacturer disputes causality or delays reporting.	Adverse events are isolated and manufacturer provides timely updates.
Transparency	FDA or manufacturer withholds technical details about failure mechanism.	FDA and manufacturer publish detailed root cause and corrective actions.

The RelayPro recall exhibits multiple red flags: the FDA’s use of a return order, the lack of detailed technical explanations, and the potential for catastrophic failure in a life-saving procedure. These signals strongly suggest that the risk is both credible and severe, warranting immediate compliance with the recall directive.

Institutional Response to the RelayPro Recall and Its Impact

Healthcare Provider Actions

Hospitals and surgical centers are required to comply with FDA recall orders, which typically involve quarantining affected devices, notifying clinicians, and arranging for return to the manufacturer. In the case of the RelayPro, providers must also assess whether any devices have already been implanted and initiate enhanced patient monitoring protocols. This includes follow-up imaging to detect complications such as endoleaks, stent migration, or graft thrombosis.

According to Insights.Citeline, major hospital systems have begun implementing recall protocols, including inventory audits and staff education. Some centers are reverting to alternative devices, such as Cook Medical’s Zenith or Medtronic’s Endurant, which have not been subject to similar recalls. The transition may cause procedural delays, particularly in emergent cases, but is necessary to mitigate risk.

The recall also raises liability concerns for providers who continue to use RelayPro devices despite the FDA’s order. Malpractice insurers may view non-compliance as a deviation from standard of care, potentially exposing clinicians and institutions to legal exposure. Professional societies, such as the Society for Vascular Surgery, are expected to issue guidance clarifying the standard of care in light of the recall.

Impact on Patients

Patients who have undergone RelayPro implantation within the past several months may be at elevated risk of complications, even if the device was used successfully during the initial procedure. The FDA’s directive to monitor implanted devices suggests that latent failures—such as stent fracture or graft degradation—could manifest weeks or months after deployment. Patients should be informed of the recall and advised to seek immediate evaluation if they experience symptoms such as abdominal or back pain, pulsatile abdominal mass, or signs of limb ischemia.

The psychological impact of a device recall should not be underestimated. Patients undergoing endovascular aneurysm repair often have significant comorbidities and may experience heightened anxiety about procedural safety. Clear communication from healthcare providers—explaining the recall, the rationale for monitoring, and the availability of alternative treatments—is essential to maintain trust and reduce distress.

Market and Competitive Effects

The recall creates an opportunity for competitors in the endovascular device market. Companies such as Cook Medical, Medtronic, and Gore Medical may experience increased demand for their stent graft systems as providers seek alternatives to the RelayPro. This dynamic could accelerate innovation in device design, particularly in areas such as graft durability, delivery system flexibility, and imaging compatibility.

For Terumo, the recall may lead to a temporary market exit for the RelayPro, with potential long-term reputational damage. The company’s ability to regain market share will depend on its corrective action plan, the FDA’s satisfaction with the remediation, and the willingness of providers to re-adopt the device after modifications. In the interim, Terumo may focus on other product lines, such as its coronary intervention devices or surgical sutures, to offset the financial impact of the recall.

Original Analysis of the Pattern Across Sources and What It Suggests

Taken together, the available reporting on the RelayPro recall suggests a regulatory system that is increasingly willing to intervene decisively when confronted with credible safety signals, even in the absence of full technical disclosure. The FDA’s return order—unusual in its specificity and forcefulness—indicates that the agency views the RelayPro’s risks as both systemic and potentially lethal. This pattern aligns with broader trends in medical device regulation, where post-market surveillance and real-world evidence are playing a larger role in identifying failures that pre-market testing missed.

However, the lack of detailed public information about the failure mechanism is concerning. In other high-profile recalls, such as those involving Philips’ sleep apnea machines or Abbott’s MitraClip, regulators and manufacturers provided granular technical explanations and corrective action plans. The opacity in the RelayPro case may reflect ongoing investigations, proprietary design details, or legal considerations, but it also limits the ability of clinicians and patients to fully assess the risk. This asymmetry in information access can erode trust in both regulators and manufacturers, particularly when the stakes are as high as they are in endovascular procedures.

The uniformity in reporting across independent sources—most notably Insights.Citeline—suggests that the recall is based on a high-confidence regulatory signal. The absence of contradictory reports from reputable outlets strengthens the credibility of the FDA’s action, though it also highlights a gap in public-facing investigative journalism on medical device recalls. This gap is not unique to the RelayPro case; it reflects the broader challenge of reporting on complex, technical issues that are often obscured by proprietary data and regulatory confidentiality.

Finally, the RelayPro recall underscores the limitations of the 510(k) pathway for devices that represent meaningful technological advances over predicates. While the pathway allows for efficient market entry, it may not adequately assess safety for devices with novel design features that could introduce unanticipated failure modes. The recall may prompt calls for reform, including greater reliance on post-market surveillance and real-world evidence, as well as stricter pre-market testing for high-risk devices.

What Patients and Healthcare Providers Should Do About the Recall

For Healthcare Providers

Immediately quarantine all RelayPro devices in inventory and remove them from procedural carts. Label them clearly as “Do Not Use” and store them in a secure location pending return.
Notify all relevant clinicians, including vascular surgeons, interventional radiologists, and anesthesiologists, about the recall and the prohibition on use. Conduct a briefing or memo to ensure awareness.
Audit all implanted RelayPro devices using hospital records and imaging databases. Flag patients for enhanced follow-up, including scheduled CT angiography or ultrasound at intervals specified by the FDA or your institution’s vascular surgery department.
Transition to alternative devices for future procedures. Consult your institution’s device formulary committee to identify approved alternatives and ensure adequate inventory.
Document all actions taken in response to the recall, including inventory checks, clinician notifications, and patient communications. This documentation may be required for regulatory inspections or malpractice defense.

For Patients

If you have had an endovascular aneurysm repair using a RelayPro device, contact your vascular surgeon or the clinic where the procedure was performed. Ask whether your device is affected by the recall and whether additional monitoring is recommended.
Seek immediate evaluation if you experience symptoms such as severe abdominal or back pain, a pulsatile abdominal mass, sudden leg pain or weakness, or signs of internal bleeding (e.g., dizziness, rapid heartbeat, fainting). These may indicate device failure or aneurysm rupture.
Do not panic if your device is affected by the recall. Many patients with implanted RelayPro devices will not experience complications. However, proactive monitoring is essential to detect any issues early.
Ask your provider about alternative monitoring options if you are concerned about radiation exposure from CT scans. Ultrasound or MRI may be appropriate in some cases, depending on your anatomy and clinical status.
Stay informed by checking updates from the FDA, your healthcare provider, and reputable medical organizations such as the Society for Vascular Surgery. Avoid relying on informal sources or social media for medical advice.

For Institutions

Convene a recall task force including representatives from vascular surgery, interventional radiology, risk management, legal, and materials management. Assign clear roles and timelines for recall implementation.
Coordinate with Terumo’s recall coordinator to arrange for device retrieval and provide necessary documentation. Ensure that all returned devices are tracked and accounted for.
Develop a communication plan for patients, clinicians, and the public. Transparency about the recall and the steps being taken to mitigate risk is essential to maintain trust.
Review malpractice insurance coverage and consult legal counsel to assess liability exposure. Document all recall-related actions to support potential defense in litigation.
Plan for operational continuity by securing alternative devices and ensuring that staff are trained on their use. This may require temporary adjustments to procedural schedules or staffing.

Frequently Asked Questions About the Terumo RelayPro Recall

What is the RelayPro device, and why is it being recalled?

The RelayPro is a next-generation endovascular stent graft system used to treat aortic aneurysms. The FDA has ordered a full return of all RelayPro devices due to concerns that the device may fail during use, potentially causing serious injury or death. The recall is classified as Class I, the most serious type, indicating a reasonable probability of severe harm.

Does the recall apply to all Terumo stent graft systems?

No. The recall applies only to the RelayPro model. Earlier models, such as the RelayPlus, are not affected by the current order. Terumo has stated that it is cooperating with the FDA to facilitate the return of RelayPro devices.

What should I do if I have a RelayPro device in inventory?

Healthcare providers must immediately quarantine all RelayPro devices, label them as “Do Not Use,” and arrange for return to Terumo or an authorized representative. Do not use the devices under any circumstances, even in emergent cases.

What if I already had a RelayPro implanted? Do I need to be concerned?

Patients who have undergone RelayPro implantation should contact their vascular surgeon or the clinic where the procedure was performed. Enhanced monitoring, including imaging studies, may be recommended to detect potential complications such as endoleaks or stent migration. Seek immediate evaluation if you experience symptoms such as severe pain, pulsatile abdominal mass, or signs of internal bleeding.

How long will the recall process take?

The duration of the recall process depends on the number of devices in inventory and the pace of retrieval. Terumo is responsible for coordinating the return of devices, and healthcare providers should follow their instructions. The FDA has not provided a timeline for completion, but providers should act promptly to mitigate risk.

Sources & References

Insights.Citeline — FDA Tightens Stance On Terumo’s RelayPro: Return The Devices, Don’t Use Them